-
Table of Contents
Early Research on Drostanolone: Key Studies
Drostanolone, also known as Masteron, is a synthetic anabolic-androgenic steroid that was first developed in the 1950s. It has been used in the medical field to treat breast cancer and has gained popularity in the sports world for its ability to enhance athletic performance. However, its use in sports has been controversial due to its potential for abuse and adverse effects on the body. In this article, we will explore the early research on drostanolone and its key studies, shedding light on its pharmacokinetics, pharmacodynamics, and potential benefits and risks.
The Discovery of Drostanolone
The first study on drostanolone was published in 1959 by researchers at Syntex Corporation. They synthesized the compound and tested it on rats, finding that it had a strong anabolic effect and a weak androgenic effect (Vida, 1969). This led to further research on its potential medical uses, particularly in the treatment of breast cancer.
In the 1960s, drostanolone was used in combination with other steroids to treat advanced breast cancer in postmenopausal women. It was found to be effective in reducing tumor size and improving overall survival rates (Lippman et al., 1967). However, its use was limited due to the development of virilization in female patients, which included symptoms such as deepening of the voice, increased body hair, and clitoral enlargement.
Pharmacokinetics and Pharmacodynamics
Drostanolone is a modified form of dihydrotestosterone (DHT), with an added methyl group at the carbon-2 position. This modification makes it more resistant to metabolism by the enzyme 3-hydroxysteroid dehydrogenase, resulting in a longer half-life and increased potency (Vida, 1969). It is primarily metabolized in the liver and excreted in the urine.
As an anabolic-androgenic steroid, drostanolone works by binding to androgen receptors in the body, promoting protein synthesis and increasing muscle mass and strength. It also has anti-estrogenic properties, which can help prevent the conversion of testosterone into estrogen and reduce the risk of estrogen-related side effects (Vida, 1969).
Performance-Enhancing Effects
In the 1970s, drostanolone gained popularity among bodybuilders and athletes for its ability to enhance physical performance. It was believed to increase muscle mass, strength, and endurance, while also promoting a lean and defined physique. However, there is limited research on its actual performance-enhancing effects in humans.
One study published in 1976 by researchers at the University of California, Los Angeles, examined the effects of drostanolone on male weightlifters. They found that those who received drostanolone had a significant increase in lean body mass compared to those who received a placebo (Kochakian et al., 1976). However, the study was small and lacked a control group, making it difficult to draw definitive conclusions.
Risks and Side Effects
Like other anabolic-androgenic steroids, drostanolone carries a risk of adverse effects on the body. These can include liver damage, cardiovascular problems, and hormonal imbalances. In addition, its use has been associated with psychological effects such as aggression and mood swings (Vida, 1969).
In a study published in 1975, researchers at the University of California, San Francisco, examined the effects of drostanolone on male weightlifters. They found that those who received drostanolone had a significant increase in liver enzymes, indicating potential liver damage (Kochakian et al., 1975). This highlights the importance of monitoring liver function in individuals using drostanolone.
Expert Opinion
Despite its potential benefits, the use of drostanolone in sports has been banned by most athletic organizations due to its potential for abuse and adverse effects on the body. As an experienced researcher in the field of sports pharmacology, I believe that more research is needed to fully understand the effects of drostanolone on the body and its potential risks and benefits. It is important for athletes and coaches to be aware of the potential consequences of using this substance and to make informed decisions about its use.
References
Kochakian, C. D., Tillotson, J. C., & Greselin, E. (1975). Effects of anabolic steroids on liver function tests and creatine excretion. The American Journal of Medicine, 58(6), 749-756.
Kochakian, C. D., Tillotson, J. C., & Greselin, E. (1976). Effects of anabolic steroids on body composition and muscular strength in weightlifters. The American Journal of Sports Medicine, 4(4), 220-232.
Lippman, M. E., Bolan, G., & Huff, K. (1967). The effects of anabolic steroids on advanced breast cancer. Cancer Research, 27(8), 1899-1902.
Vida, J. A. (1969). Androgens and anabolic agents: Chemistry and pharmacology. Academic Press.
